Clinical Trials
Zealand Pharma and Roche charge into Phase 3 with obesity drug bet
The Danish biotech company confirmed the global study will begin in the second half of 2026
- By IPP Bureau
| April 30, 2026
Zealand Pharma is pushing its obesity drug ambitions into the late stage.
The pharma powerhouse has secured a key green light with partner Roche to move petrelintide into Phase 3 trials—setting up a pivotal test in the fast-growing weight-loss market.
The Danish biotech company confirmed the global study will begin in the second half of 2026, marking a major milestone for the once-weekly treatment designed to tackle chronic weight management.
Chief Executive Adam Steensberg framed the move as a defining moment for both the drug and the partnership.
“Advancing petrelintide into Phase 3 marks an important step for the program and our collaboration with Roche. By delivering exceptional tolerability and desired weight loss without disrupting daily life, we aim to redefine the weight management experience for people living with overweight and obesity."
The late-stage program will assess how well petrelintide works—and how safely—in adults living with obesity or those overweight with related health conditions. The drug is being positioned as a more tolerable alternative in a crowded field, with the potential to improve long-term adherence, a critical challenge in weight-loss treatments.
Petrelintide is a long-acting amylin analog, designed for once-weekly injection. It mimics a naturally occurring hormone released alongside insulin, helping regulate appetite by restoring sensitivity to leptin—the hormone responsible for signaling fullness. The goal: help patients feel satisfied sooner and sustain weight loss over time.
The Phase 3 push builds on a broader alliance struck in 2025, when Zealand Pharma and Roche signed an exclusive deal to co-develop and commercialize the therapy.
Beyond standalone use, the companies are also betting on combination strategies. A Phase 2 trial pairing petrelintide with Roche’s dual GLP-1/GIP agonist enicepatide (CT-388) is slated to begin in the second quarter of 2026.
With blockbuster obesity drugs reshaping the pharmaceutical landscape, the upcoming trials will determine whether petrelintide can carve out a competitive edge—or become a serious contender in the next wave of metabolic treatments.
